REPORT HIGHLIGHTS
- In 2003, the combined worldwide market for cardiac markers, drugeluting
stents, portable automated external defibrillators, and cardiac
resynchronization therapy was estimated at $4.46 billion.
- These four areas, plus angiogenesis/gene therapy products introduced
during the forecast period, are expected to rise at an average annual growth
rate (AAGR) of 29% to nearly $16 billion in 2008.
- The first four product categories represent segments in which dramatic
change is underway. All of these areas will experience double digit growth
throughout the forecast period.
- Angiogenesis-stimulating therapies and gene therapies represent the next
revolution in this area of healthcare, with approval of the first product,
an angiogenesis-stimulating agent, possible before the end of 2004.
INTRODUCTION
Cardiovascular disease comprises conditions that affect the proper
functioning of the heart and blood vessels. Among the most prevalent of
life-threatening diseases are sudden cardiac arrest (SCA), acute myocardial
infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every
year, an estimated 17 million people worldwide die of cardiovascular disease,
particularly AMIs and strokes. Cardiovascular disease remains the leading
cause of death in developed countries. In the U.S., one person dies every 30
seconds from heart disease. This translates to more than 2,600 people a day.
Each year in the U.S., deaths from cardiovascular disease represent
approximately 42% of all deaths, or some one million deaths. Heart diseaseis the
leading cause of death for all Americans age 35 and older. This BCC report
provides an in-depth assessment of new product introductions in several
categories of cardiovascular medicine that are revolutionizing not only
diagnosis and treatment of certain cardiovascular disorders, but their markets
as well. These products include cardiac markers for the detection of AMI and CHF,
drug-eluting stents to prevent restenosis following percutaneous transluminal
coronary angioplasty, automated external defibrillators to treat patients
suffering from sudden cardiac arrest and cardiac resynchronization therapy for
the treatment of CHF. Also discussed in this report are advances in
angiogenesis stimulation to treat angina, coronary artery disease and peripheral
vascular disease, as well as gene therapy approaches to several cardiovascular
disorders.
SCOPE OF STUDY
The report contains:
- A comprehensive overview of one category of diagnostics, one category of
therapeutics and three categories of devices that are, or will be
revolutionizing the treatment of cardiovascular diseases
- A chapter on each of the five categories: cardiac markers, drug-eluting
stents, automated exexternal defibrillators, cardiac resynchronization
therapy and angiogenesis/gene therapy
- Full descriptions of the technologies involved and how these differ from
existing and emerging technologies
- Analysis of the technological approaches undertaken by the various
competitors and industry and end-user response to these products
- Regulatory issues and legislation affecting use and marketing of products
- Market forecasts for each category of product through 2008, and profiles
of selected competitors in each category are included.
METHODOLOGY
The base year for this study is 2003. Market figures are based on revenues at
the manufacturers' level and are projected at 2004-dollar value (i.e., inflation
is not computed into the projection figures). INFORMATION SOURCES Data to
prepare this study was derived from information obtained from interviews with
management at companies competing or which have products in development that
will compete in the five categories covered in the report. In addition,
interviews were conducted with physicians and other professionals working in
cardiovascular treatment centers to gain insight into clinical assessment and
usage of and preference for different therapeutics and devices, and with
laboratory personnel to gain insight into usage of diagnostics. Key information
from business literature was used to obtain expert opinions on commercial
potential and market sizes from industry professionals. | 
View Cart
